Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Rhythm Pharmaceuticals ( (RYTM) ) has shared an announcement.
On June 24, 2025, Rhythm Pharmaceuticals held its Annual Meeting of Stockholders, where stockholders approved an amendment to the company’s Certificate of Incorporation. This amendment updates the exculpation provision for certain officers, aligning with recent changes in Delaware’s General Corporation Law. The amendment was filed and became effective on June 25, 2025. Additionally, Jennifer Good and Edward T. Mathers were elected as Class II Directors, and other proposals, including the ratification of Ernst & Young LLP as the company’s accounting firm, were approved.
The most recent analyst rating on (RYTM) stock is a Buy with a $70.00 price target. To see the full list of analyst forecasts on Rhythm Pharmaceuticals stock, see the RYTM Stock Forecast page.
Spark’s Take on RYTM Stock
According to Spark, TipRanks’ AI Analyst, RYTM is a Neutral.
Rhythm Pharmaceuticals’ overall stock score reflects strong technical momentum and positive earnings call insights, which are tempered by financial performance challenges and valuation concerns. The company’s strategic advancements and robust pipeline position it well for future growth, but profitability remains a key challenge.
To see Spark’s full report on RYTM stock, click here.
More about Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc. operates in the biopharmaceutical industry, focusing on the development and commercialization of treatments for rare genetic disorders of obesity.
Average Trading Volume: 722,208
Technical Sentiment Signal: Buy
Current Market Cap: $3.96B
For an in-depth examination of RYTM stock, go to TipRanks’ Overview page.